Psychosis Seen In 63% Of Risperdal Alzheimer's Trial Patients, Janssen Says
Executive Summary
Janssen identified psychosis in 63% of patients with severe dementia in a Risperdal trial, the company said in a paper submitted to FDA's Psychopharmacologic Drugs Advisory Committee.
You may also be interested in...
Alzheimer's Psychosis Studies Should Measure Improved Functional Status
Studies of drugs for psychosis related to Alzheimer's disease should measure improvement in patients' functional status as well as amelioration of symptoms of psychosis, FDA's Psychopharmacologic Drugs Advisory Committee agreed at its March 9 meeting.
Alzheimer's Psychosis Studies Should Measure Improved Functional Status
Studies of drugs for psychosis related to Alzheimer's disease should measure improvement in patients' functional status as well as amelioration of symptoms of psychosis, FDA's Psychopharmacologic Drugs Advisory Committee agreed at its March 9 meeting.
"Agitation" Claim For Psychotropic Drugs May Be Considered By FDA
FDA may propose "agitation" as an indication for psychotropic drugs at the March 9 Psychopharmacologic Drugs Advisory Committee meeting on psychiatric and behavioral disturbances associated with dementia.